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Abstract
Background: Hepatitis B e Antigen (HBeAg)-negative chronic hepatitis B (CHB) patients have an active liver disease
with a high risk of progression to decompensated cirrhosis and hepatocellular carcinoma. The management
strategy for HBeAg-negative CHB patients treated with nucleos(t)ide analogues (NUCs) is a topic of concern. To
observe the outcomes for this population after NUCs withdrawal, HBeAg-negative CHB patients with loss of
hepatitis B surface antigen (HBsAg) or sustained undetectable HBV DNA levels who had discontinued NUCs therapy
were included in the study.
Methods: A total of 66 patients (2 patients with HBsAg loss and 64 patients with sustained undetectable HBV DNA
levels) were examined. HBV DNA levels and alanine aminotransferase (ALT) levels were monitored regularly after
discontinuation of NUCs therapy. Relapse was defined as HBV DNA levels >2,000 IU/mL while off therapy in at least
two determinations more than 4 weeks apart.
Results: The time to achieve undetectable HBV DNA levels was 14 weeks (interquartile range (IQR): 12–24 weeks).
The time until consolidation therapy was 144 weeks (IQR: 96–168 weeks). No relapses occurred in either of the
HBsAg loss patients. Among the 64 patients with undetectable HBV DNA levels, 19 (29.7%) patients demonstrated
evidence of relapse. All the relapses occurred within 96 weeks after discontinuation. The median duration of relapse
was 36 weeks (IQR: 12–48 weeks). Elevation of HBV DNA and ALT levels over baseline was only observed in 10% of
the relapse patients. There were no significant differences among the baseline characteristics (sex, HBV genotype,
age, or ALT level) or the time until consolidation therapy between relapse and sustained-response patients.
Conclusions: NUC discontinuation is feasible after achieving undetectable HBV DNA levels in HBeAg-negative
CHB patients. Prolonging the time until consolidation therapy may be a good strategy to decrease the rate of
relapse. More than 96 weeks of sustained response is a predictive marker of long-term sustained response.
Keywords: Chronic hepatitis B, HBeAg-negative, Nucleos(t)ide analogues, Discontinuation, Relapse
Background
About 350 million people worldwide live with chronic
hepatitis B virus (HBV) infection. Approximately 25% of
adults with chronic HBV infection since childhood later
die from liver cancer or cirrhosis [1]. Therefore, the goal
of chronic hepatitis B (CHB) therapy is to achieve
sustained suppression of HBV replication and remission
of liver disease. CHB may present either as hepatitis B e
antigen (HBeAg)-positive or HBeAg-negative. The pre-
valence of HBeAg-negative CHB has been increasing
over the last decade and represents the majority of cases in
many areas. The strategy of long-term treatment with
nucleos(t)ide analogues (NUCs) is necessary for HBeAg-
positive patients [2]. Unlike interferons, which are admi-
nistered for predefined durations of time owing to their
immunomodulatory effects, NUCs are generally adminis-
tered for a long duration, as long as 5–6 years or more,
until specific end points are achieved, even though HBV
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DNA levels can be suppressed to undetectable in a much
shorter period of time.
For HBeAg-negative patients, hepatitis B surface anti-
gen (HBsAg) loss is the ideal endpoint [2]. However,
previous longitudinal studies have indicated that the
annual rate of HBsAg loss is only approximately 0.5–
2.3% [3-6]. Induction of sustained off-therapy virological
and biochemical response is a satisfactory end point
[2]. However, relapse is frequent after NUCs dis-
continuation. Therefore, discontinuing or continuing
therapy after achieving the satisfactory endpoint is a
crucial decision faced by physicians and patients.
Continuing therapy is typically the preferred choice
for the majority of physicians because maintaining
undetectable HBV DNA levels does not represent
serum immunological response. Nevertheless, long-
term therapy with NUCs may cause resistance or
virological breakthrough.
Few studies have focused on the long-term outcomes
after NUCs withdrawal in HBeAg-negative CHB pa-
tients. Based on ten years of data on NUCs therapy in
HBeAg-negative CHB patients, we designed this retro-
spective study to observe the long-term outcomes of




HBeAg-negative CHB patients presenting for treat-
ment at our hospital from 2002–2008, a total of 64
with sustained undetectable HBV DNA levels and 2
patients with HBsAg loss, were included in this study
to observe the outcomes of therapy discontinuation.
The patients who started out on one antiviral agent,
such as lamivudine, and switched to another agent,
such as entecavir, because they did not have a good
response or developed resistance were classified by
the last drug used. Patients were evaluated at least
once every 3 months after discontinuation for ALT
and HBV DNA levels. Clinical data were collected,
monitored, and entered into a database. The out-
comes, including sustained response and relapse, were
evaluated during long-term follow-up for at least 24
weeks. Data were collected during follow-up appoint-
ments through January 1, 2012.
This analysis was conducted on anonymized data,
collected as part of routine patient care. No addi-
tional investigations were performed. Therefore, no
prior informed consent from the patients was requi-
red. The study protocol conformed to the ethical
guidelines of the 1975 Declaration of Helsinki as
reflected in a priori approval by the ethics committee
of Southwest Hospital, which waived the need for in-
formed consent.
Inclusion and exclusion criteria
Criteria for inclusion included: presence of serum
HBsAg for at least 6 months; negative for HBeAg; active
CHB; and serum HBV DNA levels >2,000 IU/mL, as mea-
sured by LightCycler polymerase-chain-reaction (PCR)
assay (Roche Molecular Diagnostics, Basel, Switzerland;
lower limit of detection, 200 IU/mL). An active CHB was
defined by a single serum alanine aminotransferase (ALT)
level more than 2.0 times the upper limit of normal (ULN,
40 U/L) or at least two determinations 4 weeks apart of
ALT levels 1.0–2.0×ULN.
Criteria for exclusion included: coexisting serious
medical or psychiatric illness; organ or bone marrow
transplantation; recent therapy with systemic corticoste-
roids, immunosuppressants, or chemotherapeutic agents;
a serum alpha-fetoprotein level of at least 50 ng/mL;
liver disease that was not due to hepatitis B; and sero-
positivity for human immunodeficiency virus or hepatitis
C or D virus.
Definitions of endpoints
In this study, two endpoints were considered: the ideal
and the satisfactory. The ideal endpoint was sustained
off-therapy HBsAg loss with or even without anti-HBs
seroconversion. The satisfactory endpoint was sustained
undetectable HBV DNA levels and biochemical response
for at least 96 weeks.
Definitions of outcomes after discontinuation
Outcomes after discontinuation were either ‘sustained
response’ or ‘virological relapse’. Sustained response was
defined as a sustained off-therapy virological and bio-
chemical response. Virological relapse was defined as
off-therapy HBV DNA levels >2,000 IU/mL in at least
two determinations more than 4 weeks apart.
Serological assays
Routine biochemical tests were performed using auto-
mated techniques. HBsAg, antibody to HBsAg, HBeAg,
antibody to HBeAg, and antibody to hepatitis B core
antigen were detected by ELISA (KHB, Shanghai, China)
or electrochemiluminescence (Architect®, Abbott Labora-
tories, Abbott Park, IL, USA). Antibodies to hepatitis C
virus, hepatitis D virus, and human immunodeficiency
virus were detected by routine, commercially available
enzyme immunoassays (KHB, Shanghai, China). Serum
HBV DNA levels was quantified with a commercially
available PCR assay (LightCycler®480 Real-Time PCR
System, Roche). Alpha-fetoprotein levels were detected by
routine, commercially available colorimetric assay (KHB).
The HBV genotypes were determined using a hepatitis B
virus gene type PCR fluorescence kit (Fosun, Shanghai,
China).
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Statistical methods
Continuous variables were expressed as mean ± standard
deviation (SD) for normal distributions or median and
interquartile range (IQR) for abnormal distributions.
Pearson’s chi-square tests, Kruskal-Wallis tests, Student’s
t tests, ANOVAs, the Kaplan-Meier method, and log-
rank tests were carried out as appropriate. All tests for
significance and resulting P values were two-sided, with
a level of significance of 0.05. The statistical software
used for this analysis was SPSS 18.0.
Results
Baseline demographic and clinical characteristics
Baseline demographic and clinical characteristics of the
patients are shown in Table 1. There were no significant
differences in age, sex, ALT levels, or HBV DNA levels
at baseline between patient’s with genotype B and geno-
type C. Baseline demographic and clinical characteristics
of patient’s prescribed lamivudine, adefovir, entecavir,
and telbivudine are shown in Table 2.
Time of therapy
The time to achieve undetectable HBV DNA levels was
16 weeks (IQR: 12–24 weeks). The time of consolidation
therapy was 144 weeks (IQR: 96–168 weeks). The total
time of therapy was 160 weeks (IQR: 130–190 weeks).
The time to achieve undetectable HBV DNA levels was
18 weeks (IQR: 12–24 weeks) with lamivudine, 16 weeks
(IQR: 12–24 weeks) with adefovir, 8 weeks (IQR: 4–20
weeks) with entecavir, and 36 weeks (24 and 48 weeks)
with telbivudine. The time of consolidation therapy was
192 weeks (IQR: 144–240 weeks) with lamivudine, 120
weeks (IQR: 96–144 weeks) with adefovir, 120 weeks
(IQR: 96–144 weeks) with entecavir, and 96 weeks (96
and 96 weeks) with telbivudine. The time to achieve
HBsAg loss in the two patients was 192 weeks and 288
weeks.
Long-term outcomes after therapy discontinuation
Relapse was not observed in either of the two patients
with HBsAg loss after 96 and 72 weeks. Therefore, the
long-term outcomes after therapy discontinuation in this
study focused on the patients with undetectable HBV
DNA levels.
The time of follow-up in sustained response patients
was 72 weeks (48–108 weeks). The proportion of relapse
was 29.7% (19 of 64) and of sustained response was
70.3% (45 of 64). The distribution of outcomes after
withdrawal of lamivudine, adefovir, entecavir, and
telbivudine is shown in Table 3.
To analyze the safety of relapse, ALT levels and HBV
DNA levels were compared between baseline and the
time of relapse. ALT levels higher than baseline at the
time of relapse were only seen in 5.3% (1 of 19) of relapse
patients. HBV DNA levels over baseline at the time of
relapse were only seen in 10.5% (2 of 19) of relapse pa-
tients. No fulminant hepatitis was seen in any relapse
patient. For patients with relapse, baseline and relapse
levels of ALT and HBV DNA, as well as the treatment
strategy after relapse, are shown in Table 4.
Characteristics of patients with relapse
We further analyzed the baseline characteristics and
therapy time of all patients to identify common features
of the relapse patients. All relapse cases occurred within
96 weeks after therapy discontinuation. The time of
relapse was 36 weeks (IQR: 12–48 weeks). No significant
differences were noted in sustained response compared
with relapse patients for time to undetectable HBV
DNA levels, time of consolidation therapy, baseline HBV
DNA levels, baseline ALT levels, baseline age, sex, or
genotype (Table 5).
Cumulative sustained response rate of survival analysis
To analyze the influence of multiple factors, we plot-
ted survival functions between cumulative rate of
sustained response and time of sustained response
after NUCs discontinuation. The cumulative rate of
sustained response was 71.2%. Although this analysis
was performed using multiple factors, there were no
significant differences in the cumulative rate of sustained
response when comparing sex, age group, genotype, or
baseline ALT group (Figure 1). Owing to the limited num-
ber of patients who were treated with telbivudine and
entecavir, we did not perform survival analysis according
to the different NUCs to avoid inappropriate or mislead-
ing results.
Table 1 Baseline demographic and clinical characteristics
of patients
Characteristic Genotype B Genotype C P value
Number - (%) 30 (45.5) 36 (54.5)
Male - no. (%) 20 (66.7) 30 (83.3) 0.089
Age (Mean ± SD) - yr 36±13 35±10 0.191
<29 - no. 7 9
30 - 39 - no. 15 20
>39 - no. 8 7
ALT [Median (IQR)] - ULN 2.6 (1.3-4.0) 3.2 (1.4-7.1) 0.219
<2×ULN - no. 13 14
(2–5)×ULN - no. 13 8
>5×ULN - no. 4 14
HBV DNA (Mean±SD) -
log10 IU/mL
5.6±1.4 5.6±1.5 0.908
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Discussion
In the Mediterranean region and in Southeast Asia, 50
to 80% of CHB patients are HBeAg-negative [7].
HBeAg-negative CHB may follow seroconversion from
HBeAg to anti-HBe antibodies during the immune react-
ive phase or may develop after years or decades in the
inactive carrier state. HBV variations with nucleotide
substitutions in the precore and/or the basal core pro-
moter regions are unable to express, or express low
levels, of HBeAg [8]. HBeAg-negative CHB patients have
active liver disease with a high risk of progression to
advanced hepatic fibrosis, cirrhosis, and subsequent
complications including decompensated cirrhosis and
hepatocellular carcinoma [8]. The strategy of long-term
treatment with NUCs is necessary for HBeAg-negative
CHB patients to prevent long-term sequelae. Although
the use of NUCs has greatly improved HBeAg-negative
CHB management, drug resistance is an important clin-
ical risk resulting from long-term therapy. In this retro-
spective study, we observed the outcomes after therapy
discontinuation in HBeAg-negative CHB patients after
achieving HBsAg loss or sustained undetectable HBV
DNA levels.
Relapse was not observed in patients who had
achieved HBsAg loss after at least 96 weeks. Recent
studies on HBsAg loss in HBeAg-negative patients
demonstrated that relapse did not occur during the
follow-up period [9,10]. This indicates that HBsAg
loss is the preferred endpoint for therapy discontinu-
ation. In another study, the prognosis after spontan-
eous HBsAg loss was good as long as cirrhosis did
not emerge before HBsAg loss [11]. This result im-
plies that HBsAg loss, therapy-induced or spontan-
eous, may be an ideal outcome for HBeAg-negative CHB
Table 2 Baseline demographic and clinical characteristics of the NUCs discontinuation patients treated by lamivudine,
adefovir, entecavir, and telbivudine
Characteristic LAM ADV ETV LDT
Number. (%) 15 (22.7) 42 (63.6) 7 (10.6) 2 (3.0)
Age (Mean ±SD) - yr 34.1±13.0 35.3±10.6 36.1±14.0 33.5±10.6
<29 - no. 4 9 2 1
30-39 - no. 8 24 3 0
>39 - no. 3 9 2 1
Man - no. (%) 14 (93.3) 30 (71.4) 4 (57.1) 2 (100)
ALT [Median (IQR)] - ULN 2.6 (1.2-3.5) 2.5 (1.3-6.6) 4.7 (2.7-14.0) 9.5 (3.9, 15.0)
HBV DNA - log10 IU/mL 6.3±1.6 5.3±1.3 5.5±0.8 7.0±2.2
HBsAg loss - no. (%) 2 (100) 0 0 0
LAM, lamivudine; ADV, adefovir; ETV, entecavir; LDT, telbivudine.
Table 3 Distribution of outcomes after discontinuation of
lamivudine, adefovir, entecavir, and telbivudine
NUCs Sustained response - no. (%) Relapse - no. (%)
LAM 11 (24.4) 2 (10.5)
ADV 27 (60.0) 15 (78.9)
ETV 5 (11.1) 2 (10.5)
LDT 2 (4.4) 0
LAM, lamivudine; ADV, adefovir; ETV, entecavir; LDT, telbivudine.
Table 4 Baseline and relapse levels of ALT and HBV DNA
in patients with relapse
No. NUCs HBV DNA - log10 IU/mL ALT - ULN Retreat
Baseline Relapse Baseline Relapse
1 LAM 7.70 3.39 1.67 1.02 ETV
2 LAM 7.67 3.51 3.88 1.45 ETV
3 ADV 3.91 3.35 1.43 0.57 ADV
4 ADV 4.14 3.74 2.71 0.74 ADV
5 ADV 5.88 3.41 1.48 0.36 ADV
6 ADV 5.42 5.71 7.33 4.90 ADV
7 ADV 7.71 3.41 8.00 0.83 ADV
8 ADV 3.87 3.44 1.26 1.00 ADV
9 ADV 6.32 3.43 1.31 0.98 ADV
10 ADV 5.39 3.77 1.05 0.36 ADV
11 ADV 5.86 4.06 6.69 1.21 ADV
12 ADV 3.33 3.39 1.38 0.90 ADV
13 ADV 6.37 3.60 5.07 1.31 ADV
14 ADV 5.68 4.51 6.57 1.57 ADV
15 ADV 4.42 4.15 1.08 0.98 ADV
16 ADV 4.68 3.31 1.32 0.17 ADV
17 ADV 7.39 4.06 3.55 0.60 ADV
18 ETV 4.55 5.22 2.74 1.07 ETV
19 ETV 5.63 3.68 1.19 1.29 ETV
LAM, lamivudine; ADV, adefovir; ETV, entecavir.
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patients. The inclusion criteria among these studies were
very similar.
For HBeAg-negative CHB patients, relapse is frequent
even when HBV DNA levels have been suppressed to
undetectable for more than one year, making the precise
endpoint for NUCs withdrawal unclear. The Asian Pa-
cific Association for the Study of the Liver guidelines
recommend that treatment can be discontinued if
undetectable HBV DNA levels have been documented
on three occasions ≥6 months apart. In the present
study, consolidation therapy for at least 96 weeks was
used as the satisfactory endpoint for NUCs discontinu-
ation. The proportion of relapse after NUCs discontinu-
ation was less than 30%, compared with 56% in a study
with lamivudine [9], 61.4% in a 1-year study with
adefovir [10], and 45.3% in a 1-year study with entecavir
[12]. The relapse times we measured were longer than
reported by other studies. On the one hand, the duration
of consolidation therapy was longer than in other stud-
ies. A study showed that consolidation therapy for >64
weeks seems more appropriate for those with higher
baseline HBV DNA [12]. On the other hand, short
follow-up times for some patients may have influenced
the outcomes.
Several studies of HBeAg-negative CHB patients after
NUCs withdrawal showed that age was the only predictive
factor for relapse, with lower relapse rates found in younger
patients [9,10]. An HBV DNA decrease to <20,000 IU/mL
at 12 weeks has been reported to be associated with a 50%
chance of sustained off-treatment response [13]. A study of
HBeAg-negative CHB patients after entecavir withdrawal
showed that baseline HBV DNA ≤2×105 IU/mL was the
only significant independent factor predictive of a
sustained response [12]. However, in the present study,
there were no significant differences in cumulative
sustained response rates among sex, baseline age group,
baseline ALT levels, or genotype. This implies that
there are no available routine clinical indicators to fore-
cast relapse for HBeAg-negative CHB patients. How-
ever, according to our data, the factor most likely to be
indicative of relapse or sustained response was baseline
ALT levels. This result is actually consistent with the
phenomenon of high ALT levels and high serum im-
munology response rates in HBeAg-positive CHB pa-
tients. For HBeAg-negative CHB patients, finding an
appropriate indicator reflecting serum immunological
response is necessary to determine the appropriate end-
point for NUCs discontinuation. Theoretically, in HBeAg-
negative patients who achieved a sustained response after
discontinuation, there must be a biomarker response indi-
cative of the serum immunological response. The differ-
ence in anti-HBV immunity is essential, but there is
currently no appropriate standard.
It is worth mentioning that all of relapses occurred
within 96 weeks. This is consistent with the results pub-
lished in previous studies [9,10,12], and implies that over
96 weeks of sustained response is a predictive marker
for longer-term sustained response after NUCs discon-
tinuation. Furthermore, elevated ALT levels and HBV
DNA levels over baseline at relapse was observed in
only 10% of relapse patients and no fulminant hepatitis
was seen. This suggests that the safety risk of discon-
tinuation is acceptable. In a recent study, the frequency
of NUCs withdrawal flares was estimated as 3.2 per 100
person-years in 17 (11%) of 149 therapy discontinua-
tions [14].
Two limitations in our data set should be noted.
First, the follow-up time of some patients with
sustained response was short (24 weeks in 7 patients,
and 48 weeks in 15 patients). Second, the majority of
patients used adefovir. The majority of NUCs pre-
scribed in China from 2002–2008 were lamivudine
and adefovir. Therefore, the number of patients who
were treated with telbivudine and entecavir was very
small. Based on the data from HBeAg-positive CHB
patients treated with NUCs, the difference in serum
immunology response rate among different drugs is
very small. This suggests that sustained response
depended on individual immunity to HBV rather than
the different NUCs used.
Table 5 Baseline characteristic and therapy time of relapse and sustained response (SR) patients after discontinuation
Characteristic SR (n=45) Relapse (n=19) P value
HBV DNA - log10 IU/mL 5.5±1.5 5.5±1.5 0.928
ALT – × ULN 3.0 (1.5-6.3) 1.5 (1.2-5.1) 0.154
Age - years 34±11 37±11 0.310
Man - no. (%) 34 (75.6) 14 (73.7) 0.874
Time of achieving undetectable HBV DNA levels – weeks 12 (12–24) 16 (12–24) 0.412
Consolidation therapy - weeks 120 (96–156) 144 (96–144) 0.798
Genotype B - no. (%) 19 (65.5) 10 (34.5) 0.445
Genotype C - no. (%) 26 (74.3) 9 (25.7)
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Conclusion
In conclusion, NUCs discontinuation is feasible after
achieving undetectable HBV DNA in HBeAg-negative
CHB patients. Prolonging the time of consolidation
therapy after achieving undetectable HBV DNA may be
a good strategy to decrease the rate of relapse. More
than 96 weeks of sustained response is a predictive





















Figure 1 Survival functions for the cumulative rate of sustained response and the time of sustained response after NUCs
discontinuation. The cumulative rate of sustained response was 71.2% (A). No significant difference in the cumulative rate of sustained response
was seen by sex (B, P=0.523), age group (C, P=0.445), genotype (D, P=0.322), or baseline ALT group (E, P=0.294).
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